GLP1R and coronary atherosclerosis: In the absence of other indications for these medications, such as heart failure and obesity, CAC may be a useful tool to triage the prescription of GLP1‐RAs for primary prevention in adults with diabetes to those who may derive the greatest benefit (e.g., those with high amounts of subclinical coronary atherosclerosis) (Figure 1).